Intangible Assets & R&D Capitalisation
Why a pharma company can spend ₹500 crore on a new drug and expense almost all of it immediately — while a software company spending the same amount on a new product can capitalise a meaningful chunk of it as an asset instead.
In plain English
Imagine a pharmaceutical company spends ₹500 crore over five years developing a new drug. For the first three years, scientists are exploring different molecules, running early lab tests, with no certainty any of it will actually work — this is genuine, high-uncertainty RESEARCH. In the final two years, having identified a promising molecule, the company is running late-stage clinical trials, seeking regulatory approval, and preparing for commercial manufacturing — this is DEVELOPMENT, where success is now reasonably probable. Accounting treats these two phases completely differently: research spending is expensed immediately, no matter how much is spent, while development spending, once specific criteria are met, can be recognised as an intangible ASSET on the balance sheet instead.
Words you'll need first
Original, planned investigation undertaken with the hope of gaining new scientific or technical knowledge, with no way yet to demonstrate that a specific, commercially viable product or process will actually result. Because the eventual payoff is genuinely too uncertain to call an 'asset' with confidence, Ind AS 38 requires ALL research expenditure to be expensed in the P&L as it's incurred — there is no option to capitalise research spending, however promising it might feel internally.
The application of research findings to a specific plan for producing a new or improved product or process, at a stage where technical feasibility and a realistic path to completion and future economic benefit can genuinely be demonstrated. Development expenditure MUST be capitalised as an intangible asset once a company can demonstrate a specific set of criteria — including technical feasibility, intention and ability to complete and use or sell the asset, and the ability to reliably measure the expenditure — rather than being optional; before those criteria are met, even development-stage spending is expensed like research.
Research vs Development — and why the line matters so much
Research spending
Always expensed immediately in the P&L, no matter how much is spent or how promising it looks — because the outcome is genuinely too uncertain, this early-stage spending can't be reliably called an asset yet.
Development spending (once criteria are met)
MUST be capitalised as an intangible asset, once technical feasibility, intent to complete, ability to use or sell the result, and reliable cost measurement can all be demonstrated — from that point on, this spending builds up an asset value on the balance sheet, rather than reducing current-year profit.
A worked example, with numbers
| Item | ₹ crore | Accounting treatment |
|---|---|---|
| Year 1 spending (research phase) | 40 | Expensed in P&L |
| Year 2 spending (development phase, post-feasibility) | 60 | Capitalised as intangible asset |
| Total spent | 100 | — |
- Even though the company spent an identical ₹100 crore in total building this product, only ₹40 crore ever hits the P&L as an expense — the remaining ₹60 crore sits on the balance sheet as an intangible asset, ready to be amortised gradually once the product actually launches.
- This means the company's REPORTED profit in Years 1 and 2 is ₹60 crore higher than it would have been if all R&D spending were expensed as incurred — a genuinely material difference for a company running multiple product development programmes simultaneously.
- Once the product launches, that ₹60 crore capitalised asset gets amortised over its expected useful life, spreading the cost against the revenue the product actually generates — matching cost to benefit, rather than expensing it all upfront before a single rupee of related revenue exists.
- If the product is later abandoned before launch, the capitalised ₹60 crore intangible asset has to be written off immediately as an impairment loss — the capitalisation decision comes with the risk of a later, concentrated write-off if the project doesn't pan out.
What it does to the financial statements
Impact on the P&L
- Research expenditure is always, without exception, expensed in the P&L in the period incurred — a genuine drag on current-period profit for any company investing heavily in early-stage innovation.
- Capitalised development expenditure has ZERO immediate P&L impact when incurred — instead, it's amortised gradually over the resulting product's useful life, once that product is actually ready for use or sale.
- A company that capitalises a large share of its R&D spend will show HIGHER current-period profit than an economically identical company that expenses more of its R&D, purely from this accounting classification difference.
- A sudden, large write-off of previously-capitalised development costs, when a project is abandoned, creates a concentrated, one-off P&L hit — often signalling a specific project failure rather than a broader business problem.
Impact on the Balance Sheet
- Capitalised development costs sit on the balance sheet as an intangible asset, separate from goodwill and from intangibles acquired through a business combination, which are accounted for differently.
- This capitalised asset is amortised over its useful life once the related product or process is ready for use — reducing the asset's carrying value gradually, mirroring how Property, Plant & Equipment is depreciated.
- A company with a large capitalised development asset balance is carrying real future amortisation charges that will flow through future P&Ls — useful to factor into forward earnings estimates.
- Unlike goodwill, capitalised development costs ARE routinely amortised, not merely tested for impairment — though they're also separately tested for impairment if there are indicators the related product won't deliver the expected benefits.
Which standard covers this
In India this is governed by Ind AS 38 – Intangible Assets, notified under the Companies (Indian Accounting Standards) Rules and applicable to companies that follow Ind AS, setting out the specific criteria that must ALL be met before development expenditure can be capitalised, and mandating that research expenditure always be expensed.
How it's recognised globally
Globally, the equivalent is IAS 38, and Ind AS 38 mirrors its research/development distinction and capitalisation criteria closely. The United States takes a meaningfully different, generally more conservative approach: under US GAAP, most R&D expenditure — including a large share of what IAS 38/Ind AS 38 would classify as capitalisable 'development' spending — is required to be expensed as incurred, with capitalisation permitted only in narrower specific circumstances. This means a US company and an Indian or European company spending economically identical amounts on R&D can report meaningfully different profit and asset figures, purely because of this difference in default treatment — a genuinely important adjustment when comparing an Indian or European pharma or technology company's reported margins against a US peer.
Real example — Indian listed company
Indian pharmaceutical companies like Sun Pharma are a natural real-world illustration of how conservatively R&D capitalisation tends to be applied in an industry where regulatory approval genuinely remains uncertain until the very end of a drug's development journey. For most pharma R&D programmes, technical and regulatory uncertainty persists deep into clinical trials — a drug candidate can still fail in late-stage trials or be rejected by regulators even after years of promising development work — so the criteria for capitalising development costs under Ind AS 38 are, in practice, rarely met until very close to actual regulatory approval. This is why large Indian pharmaceutical companies typically expense the large majority of their R&D spending as incurred, rather than building up a large capitalised development asset on the balance sheet, even while spending hundreds of crores of rupees annually on genuine drug development — a useful, real illustration of exactly the industry-specific conservatism this article's comparison highlights, standing in contrast to how a technology company's product development spending is often treated.
Where you'll see this
Related concepts
Inventory Valuation
Why two companies holding the exact same 1,000 sacks of rice in their warehouse can report two different profit numbers — just from how they count the cost of what was sold.
Depreciation Methods
Why the exact same ₹10 crore machine can show a different profit impact every year for a decade, depending on nothing more than which depreciation method a company picked on day one.
Borrowing Costs Capitalisation
Why the interest a company pays on a loan taken to build a new factory doesn't always show up as an 'interest expense' in the P&L — sometimes it quietly becomes part of the factory's cost instead.